1-18 of 18
Alberto Bardelli
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients

Giovanni Crisafulli, Andrea Sartore-Bianchi, Luca Lazzari, Filippo Pietrantonio, Alessio Amatu, Marco Macagno, Ludovic Barault, Andrea Cassingena, Alice Bartolini, Paolo Luraghi, Gianluca Mauri, Paolo Battuello, Nicola Personeni, Maria Giulia Zampino, Valeria Pessei, Pietro Paolo Vitiello, Federica Tosi, Laura Idotta, Federica Morano, Emanuele Valtorta, Emanuela Bonoldi, Giovanni Germano, Federica Di Nicolantonio, Silvia Marsoni, Salvatore Siena, Alberto Bardelli
Journal: Cancer Discovery
Cancer Discov (2022) 12 (7): 1656–1675.
https://doi.org/10.1158/2159-8290.CD-21-1434
Published: 06 July 2022
View article titled, Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
Open the PDF for Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

Gabriele Picco, Chiara M. Cattaneo, Esmée J. van Vliet, Giovanni Crisafulli, Giuseppe Rospo, Sarah Consonni, Sara F. Vieira, Iñigo Sánchez Rodríguez, Carlotta Cancelliere, Ruby Banerjee, Luuk J. Schipper, Daniele Oddo, Krijn K. Dijkstra, Jindrich Cinatl, Martin Michaelis, Fengtang Yang, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Salvatore Siena, Sabrina Arena, Emile E. Voest, Alberto Bardelli, Mathew J. Garnett
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2021) 11 (8): 1923–1937.
https://doi.org/10.1158/2159-8290.CD-20-1508
Published: 01 August 2021
View article titled, Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
Open the PDF for Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy in another window
Includes: Supplementary data
Journal Articles

Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment

Mariangela Russo, Alberto Sogari, Alberto Bardelli
Journal: Cancer Discovery
Cancer Discov (2021) 11 (8): 1886–1895.
https://doi.org/10.1158/2159-8290.CD-20-1588
Published: 01 August 2021
View article titled, Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment
Open the PDF for Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment in another window
Journal Articles

CD4 T Cell–Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair–Deficient Tumors

Giovanni Germano, Steve Lu, Giuseppe Rospo, Simona Lamba, Benoit Rousseau, Sonia Fanelli, Denise Stenech, Dung T. Le, John Hays, Maria Grazia Totaro, Vito Amodio, Rosaria Chilà, Anna Mondino, Luis A. Diaz, Jr., Federica Di Nicolantonio, Alberto Bardelli
Journal: Cancer Discovery
Cancer Discov (2021) 11 (7): 1844–1859.
https://doi.org/10.1158/2159-8290.CD-20-0987
Published: 01 July 2021
View article titled, CD4 T Cell–Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair–Deficient Tumors
Open the PDF for CD4 T Cell–Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair–Deficient Tumors in another window
Includes: Supplementary data
Journal Articles

TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

Emiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, Alison M. Schram, Helen H. Won, Sophie Shifman, Amanda Kulick, Laura Baldino, Eneda Toska, Amaia Arruabarrena-Aristorena, Srushti Kittane, Fan Wu, Yanyan Cai, Sabrina Arena, Benedetta Mussolin, Ram Kannan, Neil Vasan, Alexander N. Gorelick, Michael F. Berger, Ofra Novoplansky, Sankar Jagadeeshan, Yi Liao, Uwe Rix, Sandra Misale, Barry S. Taylor, Alberto Bardelli, Jaclyn F. Hechtman, David M. Hyman, Moshe Elkabets, Elisa de Stanchina, Chandra S. Verma, Andrea Ventura, Alexander Drilon, Maurizio Scaltriti
Journal: Cancer Discovery
Cancer Discov (2021) 11 (1): 126–141.
https://doi.org/10.1158/2159-8290.CD-20-0571
Published: 06 January 2021
View article titled, TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors
Open the PDF for TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors in another window
Includes: Supplementary data
Journal Articles

EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Vito Amodio, Rona Yaeger, Pamela Arcella, Carlotta Cancelliere, Simona Lamba, Annalisa Lorenzato, Sabrina Arena, Monica Montone, Benedetta Mussolin, Yu Bian, Adele Whaley, Marika Pinnelli, Yonina R. Murciano-Goroff, Efsevia Vakiani, Nicola Valeri, Wei-Li Liao, Anuja Bhalkikar, Sheeno Thyparambil, Hui-Yong Zhao, Elisa de Stanchina, Silvia Marsoni, Salvatore Siena, Andrea Bertotti, Livio Trusolino, Bob T. Li, Neal Rosen, Federica Di Nicolantonio, Alberto Bardelli, Sandra Misale
Journal: Cancer Discovery
Cancer Discov (2020) 10 (8): 1129–1139.
https://doi.org/10.1158/2159-8290.CD-20-0187
Published: 03 August 2020
View article titled, EGFR Blockade Reverts Resistance to KRAS<sup>G12C</sup> Inhibition in Colorectal Cancer
Open the PDF for EGFR Blockade Reverts Resistance to KRAS<sup>G12C</sup> Inhibition in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

Lipika Goyal, Lei Shi, Leah Y. Liu, Ferran Fece de la Cruz, Jochen K. Lennerz, Srivatsan Raghavan, Ignaty Leschiner, Liudmila Elagina, Giulia Siravegna, Raymond W.S. Ng, Phuong Vu, Krushna C. Patra, Supriya K. Saha, Raul N. Uppot, Ron Arellano, Stephanie Reyes, Takeshi Sagara, Sachie Otsuki, Brandon Nadres, Heather A. Shahzade, Ipsita Dey-Guha, Isobel J. Fetter, Islam Baiev, Emily E. Van Seventer, Janet E. Murphy, Cristina R. Ferrone, Kenneth K. Tanabe, Vikram Deshpande, James J. Harding, Rona Yaeger, Robin K. Kelley, Alberto Bardelli, A. John Iafrate, William C. Hahn, Cyril H. Benes, David T. Ting, Hiroshi Hirai, Gad Getz, Dejan Juric, Andrew X. Zhu, Ryan B. Corcoran, Nabeel Bardeesy
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2019) 9 (8): 1064–1079.
https://doi.org/10.1158/2159-8290.CD-19-0182
Published: 01 August 2019
View article titled, TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
Open the PDF for TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

The Clinical Impact of the Genomic Landscape of Mismatch Repair–Deficient Cancers

Giovanni Germano, Nabil Amirouchene-Angelozzi, Giuseppe Rospo, Alberto Bardelli
Journal: Cancer Discovery
Cancer Discov (2018) 8 (12): 1518–1528.
https://doi.org/10.1158/2159-8290.CD-18-0150
Published: 03 December 2018
View article titled, The Clinical Impact of the Genomic Landscape of Mismatch Repair–Deficient Cancers
Open the PDF for The Clinical Impact of the Genomic Landscape of Mismatch Repair–Deficient Cancers in another window
Journal Articles

Tumor Evolution as a Therapeutic Target

Nabil Amirouchene-Angelozzi, Charles Swanton, Alberto Bardelli
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2017) 7 (8): 805–817.
https://doi.org/10.1158/2159-8290.CD-17-0343
Published: 01 August 2017
View article titled, Tumor Evolution as a Therapeutic Target
Open the PDF for Tumor Evolution as a Therapeutic Target in another window
Journal Articles

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

Lipika Goyal, Supriya K. Saha, Leah Y. Liu, Giulia Siravegna, Ignaty Leshchiner, Leanne G. Ahronian, Jochen K. Lennerz, Phuong Vu, Vikram Deshpande, Avinash Kambadakone, Benedetta Mussolin, Stephanie Reyes, Laura Henderson, Jiaoyuan Elisabeth Sun, Emily E. Van Seventer, Joseph M. Gurski, Jr, Sabrina Baltschukat, Barbara Schacher-Engstler, Louise Barys, Christelle Stamm, Pascal Furet, David P. Ryan, James R. Stone, A. John Iafrate, Gad Getz, Diana Graus Porta, Ralph Tiedt, Alberto Bardelli, Dejan Juric, Ryan B. Corcoran, Nabeel Bardeesy, Andrew X. Zhu
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2017) 7 (3): 252–263.
https://doi.org/10.1158/2159-8290.CD-16-1000
Published: 05 March 2017
View article titled, Polyclonal Secondary <em>FGFR2</em> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
Open the PDF for Polyclonal Secondary <em>FGFR2</em> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer

Filippo Pietrantonio, Daniele Oddo, Annunziata Gloghini, Emanuele Valtorta, Rosa Berenato, Ludovic Barault, Marta Caporale, Adele Busico, Federica Morano, Ambra Vittoria Gualeni, Alessandra Alessi, Giulia Siravegna, Federica Perrone, Maria Di Bartolomeo, Alberto Bardelli, Filippo de Braud, Federica Di Nicolantonio
Journal: Cancer Discovery
Cancer Discov (2016) 6 (9): 963–971.
https://doi.org/10.1158/2159-8290.CD-16-0297
Published: 31 August 2016
View article titled, MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <em>BRAF</em>-Mutated Colorectal Cancer
Open the PDF for MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <em>BRAF</em>-Mutated Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

Mariangela Russo, Giulia Siravegna, Lawrence S. Blaszkowsky, Giorgio Corti, Giovanni Crisafulli, Leanne G. Ahronian, Benedetta Mussolin, Eunice L. Kwak, Michela Buscarino, Luca Lazzari, Emanuele Valtorta, Mauro Truini, Nicholas A. Jessop, Hayley E. Robinson, Theodore S. Hong, Mari Mino-Kenudson, Federica Di Nicolantonio, Ashraf Thabet, Andrea Sartore-Bianchi, Salvatore Siena, A. John Iafrate, Alberto Bardelli, Ryan B. Corcoran
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2016) 6 (2): 147–153.
https://doi.org/10.1158/2159-8290.CD-15-1283
Published: 04 February 2016
View article titled, Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Open the PDF for Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer

Mariangela Russo, Sandra Misale, Ge Wei, Giulia Siravegna, Giovanni Crisafulli, Luca Lazzari, Giorgio Corti, Giuseppe Rospo, Luca Novara, Benedetta Mussolin, Alice Bartolini, Nicholas Cam, Roopal Patel, Shunqi Yan, Robert Shoemaker, Robert Wild, Federica Di Nicolantonio, Andrea Sartore Bianchi, Gang Li, Salvatore Siena, Alberto Bardelli
Journal: Cancer Discovery
Cancer Discov (2016) 6 (1): 36–44.
https://doi.org/10.1158/2159-8290.CD-15-0940
Published: 07 January 2016
View article titled, Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Open the PDF for Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer

Eunice L. Kwak, Leanne G. Ahronian, Giulia Siravegna, Benedetta Mussolin, Darrell R. Borger, Jason T. Godfrey, Nicholas A. Jessop, Jeffrey W. Clark, Lawrence S. Blaszkowsky, David P. Ryan, Jochen K. Lennerz, A. John Iafrate, Alberto Bardelli, Theodore S. Hong, Ryan B. Corcoran
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2015) 5 (12): 1271–1281.
https://doi.org/10.1158/2159-8290.CD-15-0748
Published: 03 December 2015
View article titled, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in <em>MET</em>-Amplified Esophagogastric Cancer
Open the PDF for Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in <em>MET</em>-Amplified Esophagogastric Cancer in another window
Includes: Supplementary data
Journal Articles

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution

Sandra Misale, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Salvatore Siena, Alberto Bardelli
Journal: Cancer Discovery
Cancer Discov (2014) 4 (11): 1269–1280.
https://doi.org/10.1158/2159-8290.CD-14-0462
Published: 01 November 2014
View article titled, Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
Open the PDF for Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution in another window
Journal Articles

Climbing RAS, the Everest of Oncogenes

Mariangela Russo, Federica Di Nicolantonio, Alberto Bardelli
Journal: Cancer Discovery
Cancer Discov (2014) 4 (1): 19–21.
https://doi.org/10.1158/2159-8290.CD-13-0906
Published: 07 January 2014
View article titled, Climbing RAS, the Everest of Oncogenes
Open the PDF for Climbing RAS, the Everest of Oncogenes in another window
Journal Articles

Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

Alberto Bardelli, Simona Corso, Andrea Bertotti, Sebastijan Hobor, Emanuele Valtorta, Giulia Siravegna, Andrea Sartore-Bianchi, Elisa Scala, Andrea Cassingena, Davide Zecchin, Maria Apicella, Giorgia Migliardi, Francesco Galimi, Calogero Lauricella, Carlo Zanon, Timothy Perera, Silvio Veronese, Giorgio Corti, Alessio Amatu, Marcello Gambacorta, Luis A. Diaz, Jr, Mark Sausen, Victor E. Velculescu, Paolo Comoglio, Livio Trusolino, Federica Di Nicolantonio, Silvia Giordano, Salvatore Siena
Journal: Cancer Discovery
Cancer Discov (2013) 3 (6): 658–673.
https://doi.org/10.1158/2159-8290.CD-12-0558
Published: 06 June 2013
View article titled, Amplification of the <em>MET</em> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Open the PDF for Amplification of the <em>MET</em> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

Andrea Bertotti, Giorgia Migliardi, Francesco Galimi, Francesco Sassi, Davide Torti, Claudio Isella, Davide Corà, Federica Di Nicolantonio, Michela Buscarino, Consalvo Petti, Dario Ribero, Nadia Russolillo, Andrea Muratore, Paolo Massucco, Alberto Pisacane, Luca Molinaro, Emanuele Valtorta, Andrea Sartore-Bianchi, Mauro Risio, Lorenzo Capussotti, Marcello Gambacorta, Salvatore Siena, Enzo Medico, Anna Sapino, Silvia Marsoni, Paolo M. Comoglio, Alberto Bardelli, Livio Trusolino
Journal: Cancer Discovery
Cancer Discov (2011) 1 (6): 508–523.
https://doi.org/10.1158/2159-8290.CD-11-0109
Published: 16 November 2011
View article titled, A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Open the PDF for A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer in another window
Includes: Supplementary data